Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts

BACKGROUND: Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing tumour response in clear cell renal cell carcinoma (cRCC), but resistance to therapy is inevitable. As COX-2 is a known mediator of tumour growth, we explored the potential benefit of COX-2 inhibition in comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, X, Zhang, L, O'Neill, A, Bahamon, B, Alsop, D C, Mier, J W, Goldberg, S N, Signoretti, S, Atkins, M B, Wood, C G, Bhatt, R S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566808/
https://www.ncbi.nlm.nih.gov/pubmed/23322198
http://dx.doi.org/10.1038/bjc.2012.591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566808/
https://www.ncbi.nlm.nih.gov/pubmed/23322198
http://dx.doi.org/10.1038/bjc.2012.591

Ejemplares similares